Funded Biotechnology Startups in Belgium
Across the 36 most recent Belgium biotechnology rounds shown here, the largest disclosed deal is Coultreon Biopharma’s $125M Series A on 2026-04-28.
Across the 36 most recent Belgium biotechnology rounds shown here, the largest disclosed deal is Coultreon Biopharma’s $125M Series A on 2026-04-28. That figure dwarfs most other disclosed rounds in the table: the next-largest disclosed amounts are Augustine Therapeutics ($84M on 2025-03-24) and AgomAb Therapeutics ($89M on 2024-10-25), while many entries cluster well below $25M (e.g., neuroClues at $12M on 2026-04-06; Bio-Sourcing at $11M on 2024-09-24). Timing clusters are also visible: three rounds close between 2026-01-20 and 2026-04-28 (Trince $6M on 2026-01-20; neuroClues $12M on 2026-04-06; Coultreon Biopharma $125M on 2026-04-28). Geographic concentration appears around Brabant Wallon and Oost-Vlaanderen, with repeat activity from Mont-saint-guibert (e.g., Nyxoah $15M on 2026-06-17; Cognivia $17M on 2024-04-18) and Gent/Zwijnaarde (e.g., Animab $12M on 2025-07-01; 4Tissue $1M on 2025-02-26; ExeVir Bio $42M on 2020-07-28). The temporal window spans 2020-02-14 (OncoDNA) through the latest round date 2026-06-24 (Zymofix), and “Series Unknown” shows up frequently (13 rows), alongside one explicit “undisclosed” amount (FOx Biosystems, 2022-12-19).
Most recent rounds
36 shownRelated listings
Frequently asked
Which disclosed round is the outlier by size, and how does it compare to the rest of the table?
Coultreon Biopharma’s $125M Series A on 2026-04-28 is the top disclosed amount across these 36 entries, materially above the next-largest disclosed rounds: AgomAb Therapeutics at $89M (2024-10-25) and Augustine Therapeutics at $84M (2025-03-24). Most other disclosed deals sit much closer to the teens and single-digit millions (e.g., neuroClues $12M on 2026-04-06; Santero Therapeutics $9M on 2023-06-08).
Do rounds cluster into a narrow recent time window?
Yes. In early 2026, three notable disclosed rounds appear within roughly 100 days: Trince ($6M) on 2026-01-20, neuroClues ($12M) on 2026-04-06, and Coultreon Biopharma ($125M) on 2026-04-28. The overall date span runs from OncoDNA on 2020-02-14 to the most recent entry, Zymofix on 2026-06-24.
Are any locations over-represented, based on repeated city names?
Mont-saint-guibert shows repeat activity, including Nyxoah ($15M) on 2026-06-17 and Cognivia ($17M) on 2024-04-18. Gent/Zwijnaarde also recur via Animab ($12M) in Gent on 2025-07-01, 4Tissue ($1M) in Zwijnaarde on 2025-02-26, and ExeVir Bio ($42M) in Zwijnaarde on 2020-07-28.
What stage mix dominates, and where do “Series Unknown” deals show up?
Series Unknown appears on 13 of the 36 rows, spanning recent and older rounds such as Zymofix ($2M) on 2026-06-24 and Hedera-22 ($2M) on 2024-08-14. Disclosed named stages still recur (e.g., multiple Series A and B entries), but “Series Unknown” is the most frequent label among the rows.
Which edge cases are worth flagging when analyzing disclosed deal sizes?
FOx Biosystems (Temse) is the only row with an explicit “undisclosed” amount (2022-12-19), so it can’t be used in size comparisons. At the low end, Vivagran’s $100K Pre-Seed on 2024-05-14 sits far below the rest of the disclosed amounts, creating a clear small-deal tail compared with larger rounds like Precirix ($88M on 2022-03-16) and Univercells ($43M on 2022-10-19).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.